The Effects of Continuous Ambulatory Peritoneal Dialysis and Hemodialysis on Serum Pepsinogen Concentrations in Patients with Chronic Renal Failure

Aydemır, Selim; Borazan, Ali; Açıkgöz, Şerefden; Üstündağ, Yücel; Yılmaz, Ahmet

doi:10.1620/tjem.205.263

Cited by 4 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Japan, recently, the combination of serum PG level and H. pylori -IgG level had been used mainly at health check-ups as useful markers for gastric cancer screening, namely, the ABC method[37]. However, because the kidney was the key organ for eliminating serum PGs[38], serum PG levels were elevated in chronic kidney disease (CKD) patients including those who received hemodialysis compared with control subjects with normal renal function[27,39,40]. Araki et al[40] reported that serum PG I and PG II levels and PG I/II ratio measured by radioimmunoassay (RIA), which strong correlation was proved between assays of EIA and RIA[41-43], in H. pylori -negative subjects with normal renal function were 50.7 ± 28.7 ng/mL, 10.2 ± 6.1 ng/mL and 5.5 ± 2.4, respectively, while in this study, those parameters were 551.8 ± 319.2 ng/mL, 46.4 ± 24.5 ng/mL and 12.2 ± 4.5 in the non-infection group and 268.3 ± 238.0 ng/mL, 51.0 ± 39.9 ng/mL and 5.3 ± 2.9 in the present infection group, respectively.…”

Section: Discussionmentioning

confidence: 99%

Relationship between ghrelin,Helicobacter pyloriand gastric mucosal atrophy in hemodialysis patients

Ichikawa¹,

Sugimoto²,

Sakao³

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo investigate the relationship between plasma ghrelin level, Helicobacter pylori (H. pylori) infection status and the severity of atrophy in hemodialysis patients.METHODSOne hundred eights patients who received hemodialysis and 13 non-hemodialysis H. pylori-negative controls underwent gastroduodenoscopy to evaluate the severity of gastric atrophy. Serum levels of pepsinogen (PG) were measured as serum markers of gastric atrophy. H. pylori infection was evaluated by anti-H. pylori IgG antibody, rapid urease test and culture test. We classified H. pylori infection status as non-infection, present infection and past infection. In addition, plasma acyl-ghrelin and desacyl-ghrelin levels were measured by enzyme-linked immunosorbent assay.RESULTSInfection rate of H. pylori was 45.4% (49/108). Acyl-ghrelin level in the non-infection group (39.4 ± 23.0 fmol/mL) was significantly higher than in the past (23.4 ± 19.9 fmol/mL, P = 0.005) and present infection groups (19.5 ± 14.0 fmol/mL, P < 0.001). Furthermore, desacyl-ghrelin level in the non-infection group (353.2 ± 190.2 fmol/mL) was significantly higher than those in the past (234.9 ± 137.5 fmol/mL, P = 0.008) and present infection groups (211.8 ± 124.2 fmol/mL, P < 0.001). Acyl-ghrelin was positively correlated with the PG I level and PG I/II ratio (|R| = 0.484, P < 0.001 and |R| = 0.403, P < 0.001, respectively). Both ghrelins were significantly decreased in accordance with the progress of endoscopic atrophy (both P < 0.001) and acyl-ghrelin was significantly lower in patients with mild, moderate and severe atrophy (24.5 ± 23.1 fmol/mL, 20.2 ± 14.9 fmol/mL and 18.3 ± 11.8 fmol/mL) than in those with non-atrophy (39.4 ± 22.2 fmol/mL, P = 0.039, P = 0.002 and P < 0.001, respectively).CONCLUSIONIn hemodialysis patients, plasma ghrelin level was associated with the endoscopic and serological severity of atrophy related to H. pylori infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship between ghrelin,Helicobacter pyloriand gastric mucosal atrophy in hemodialysis patients

Ichikawa¹,

Sugimoto²,

Sakao³

et al. 2016

WJG

View full text Add to dashboard Cite

show abstract

“…Although the kidney was a key organ for eliminating serum PGs [21] , PG levels were elevated in HD patients compared with subjects with normal renal function [22][23][24] ; using multiple regression analysis, PG level as a marker of gastric mucosal atrophy, as observed in subjects with normal renal function, was found to be the most influential determinant for plasma acyl and des-acyl ghrelin levels in HD patients. However, it could not use serum PGs levels as a promising biomarker of gastric atrophy in HD patients at same standard used in subjects with normal renal function.…”

Section: Discussionmentioning

confidence: 93%

Severity of Gastric Mucosal Atrophy Is the Major Determinant of Plasma Ghrelin Level in Hemodialysis Patients

Sakao

Sugimoto²,

Ichikawa³

et al. 2016

Am J Nephrol

View full text Add to dashboard Cite

Background: Ghrelin, an orexigenic hormone, has multiple favorable functions including protein anabolism enhancement, anti-inflammatory actions, and cardiovascular protection. A low plasma ghrelin level is associated with increased mortality in patients treated with hemodialysis (HD). However, it is unclear whether the plasma ghrelin level in HD patients correlates with the severity of gastric mucosal atrophy and Helicobacter pylori status. Methods: Seventy-eight maintenance HD patients and 51 non-dialysis patients with chronic kidney disease were evaluated for severity of gastric mucosal atrophy by gastroduodenoscopy and for H. pylori status using an anti-H. pylori-antibody and rapid urease test. Plasma acyl and des-acyl ghrelin levels were measured and their associations with relevant clinical parameters were investigated. Results: Des-acyl ghrelin level in HD patients was significantly higher than that in patients with kidney function preserved. Although acyl and des-acyl ghrelin levels were similar between current H. pylori positive and negative HD patients, both levels decreased significantly with the progress of endoscopic gastric mucosal atrophy in HD patients. Serum pepsinogen (PG) I level and PG I/II ratio decreased significantly according to the severity of atrophy in HD patients and positively significantly correlated with both ghrelin levels. Multiple regression analysis showed significant positive correlations between acyl ghrelin and PG I levels (β = 0.738, p < 0.001) and significant negative correlations between ghrelin and age, albumin, and creatinine levels. Conclusions: Gastric atrophy is the major determinant of ghrelin level in HD patients. Management practices, such as H. pylori eradication, before advanced atrophy may be required to prevent the decrease of ghrelin levels and improve the prognosis of HD patients.

show abstract

“…One of the possible reasons for negative correlations between in situ and serum expression of PGI or PGII may be that the majority of PGs production are restricted to gastric mucosa, and only about 1% are released into blood, which may lead to nonsynchronous alterations between in situ and serum PGs expressions [1]. Another possible reason is that, apart from the influence of PGs production in stomach, the inflow of PGs from gastric epithelial cell to blood may be affected by other potential factors, such as different damage degrees of gastric epithelial cells, different vascular permeability, and different metabolic mechanisms between in situ and serum PGs [22]. Interestingly, we observed a borderline correlation in the total study sample and a statistical correlation in GA cases between in situ and serum levels of PGI/II ratio.…”

Section: Discussionmentioning

confidence: 99%

Pepsinogen I and II expressions in situ and their correlations with serum pesignogen levels in gastric cancer and its precancerous disease

Sun

et al. 2013

BMC Clin Pathol

View full text Add to dashboard Cite

BackgroundSerum pepsinogen (PG) I/II ratio has been widely used as “serological biopsy” for the screening of gastric cancer (GC) and atrophic gastritis (GA). However, study concerning in situ expression of PGs is currently insufficient, particularly for their relationship with serum PGs levels. This study was designed to investigate in situ expression of PGI and PGII in subjects with normal mucosa (NOR), superficial gastritis (GS), GA and GC, and to evaluate the correlations between PGs expressions in situ and in serum.Methods185 subjects were enrolled for the study, including 30 NOR, 70 GS, 54 GA and 31 GC. PGI and PGII expressions in situ and in serum were detected by immunohistochemistry and enzyme-linked immunosorbent assay (ELISA) respectively. H. pylori immunoglobulin (Ig) G was also determined by ELISA.ResultsIn situ expressions of PGI, PGII and PGI/II ratio consistently decreased in sequence of NOR/GS- > GA- > GC. The expressions of PGI, PGII and PGI/II ratio in situ were statistically higher in youngers than in olders (P < 0.05). In the NOR subjects, PGI staining was statistically higher in males than that in females (p = 0.02). For the correlations between in situ and serum expressions of PGI, PGII and PGI/II ratio, a borderline correlation in the total study sample (r = 0.131, P = 0.076) and a statistical correlation in GA cases (r = 0.307, P = 0.027) were observed for the PGI/II ratio. The PGI expression correlated well with that of PGII in situ and in serum.ConclusionsThe in situ levels of PGI, PGII and PGI/II ratio sharply decreased in the GA and GC cases. The youngers exhibited higher levels of PGI, PGII and PGI/II ratios than the olders. The in situ PGI/II ratio rather than PGI and PGII alone showed certain correlation with that in serum, and the PGI expression correlated well with PGII expression. Further studies with large-scale samples are still required to validate our findings.

show abstract

The Effects of Continuous Ambulatory Peritoneal Dialysis and Hemodialysis on Serum Pepsinogen Concentrations in Patients with Chronic Renal Failure

Cited by 4 publications

References 20 publications

Relationship between ghrelin,Helicobacter pyloriand gastric mucosal atrophy in hemodialysis patients

Relationship between ghrelin,Helicobacter pyloriand gastric mucosal atrophy in hemodialysis patients

Severity of Gastric Mucosal Atrophy Is the Major Determinant of Plasma Ghrelin Level in Hemodialysis Patients

Pepsinogen I and II expressions in situ and their correlations with serum pesignogen levels in gastric cancer and its precancerous disease

Contact Info

Product

Resources

About